Beta-carotene as a novel therapy for the treatment of "Autistic like behavior" in animal models of Autism

Behav Brain Res. 2019 May 17:364:469-479. doi: 10.1016/j.bbr.2017.09.041. Epub 2017 Sep 28.

Abstract

Autism-affected individuals are characterized by lower plasma oxytocin and its ectoenzyme regulator CD38. Oxytocin, a hypothalamic hormone secreted upon the release of CD38, plays a role in social behavior and bonding. All-trans retinoic acid is a potent inducer of CD38 and can be used as a novel therapeutic strategy in autism. We investigated the role of beta-carotene in rescuing autistic-like behavior in BALB/c and BTBR mice. Beta-carotene derivatives are preferred as they are neither toxic nor teratogenic. Beta-carotene at 0.1-5.0 mg/kg was administered orally to BALB/c and BTBR newborn mice on days 1-7. They were tested at age 2-3 months for five behavioral tests for "autism"; in addition, brain CD38, oxytocin, oxytocin receptor, Brain Derived Neurotrophic Factor (BDNF) and retinoic acid receptor gene expression, serum oxytocin levels, and neurological score were evaluated. Beta-carotene administered at birth significantly increased T-maze alternations and led to longer time spent with an unfamiliar mouse in the "three-chamber test" and less time spent in the empty chamber. Furthermore, enhanced activity in the open field test; increased time spent in the reciprocal social interaction test; decreased grooming and bedding behaviors; and enhanced brain CD38, oxytocin, oxytocin receptor, BDNF, retinoic acid gene expression, and serum oxytocin levels. No changes in neurological score were observed. Beta-carotene oral supplementation to BALB/c and BTBR mice at birth significantly reduced restricted and stereotyped behaviors and interests, increased social interactions and communication, CD38, and oxytocin, probably by enhancing brain neuroplasticity without toxicity. Thus, beta-carotene administered after birth to newborns of families predisposed to "autism" has the potential to prevent/ameliorate" autistic like behavior". These results support further clinical studies.

Keywords: Animal models; Autism; BDNF; Behavioral studies; Beta-carotene; Brain; CD38; Oxytocin; Retinoic acid receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1 / metabolism
  • Animals
  • Animals, Newborn
  • Autism Spectrum Disorder / drug therapy
  • Autistic Disorder / drug therapy*
  • Behavior, Animal / drug effects*
  • Brain-Derived Neurotrophic Factor / metabolism
  • Disease Models, Animal
  • Female
  • Interpersonal Relations
  • Male
  • Membrane Glycoproteins / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Oxytocin / metabolism
  • Receptors, Retinoic Acid / metabolism
  • Social Behavior
  • beta Carotene / metabolism
  • beta Carotene / pharmacology*

Substances

  • Bdnf protein, mouse
  • Brain-Derived Neurotrophic Factor
  • Membrane Glycoproteins
  • Receptors, Retinoic Acid
  • beta Carotene
  • Oxytocin
  • Cd38 protein, mouse
  • ADP-ribosyl Cyclase 1